|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Rooks, MG, Veiga, P, Wardwell-Scott, LH, Tickle, T, Segata, N, Michaud, M, Gallini, CA, Beal, C, van Hylckama-Vlieg, JE, Ballal, SA, Morgan, XC, Glickman, JN, Gevers, D, Huttenhower, C, Garrett, WS|
|Journal||The ISME journal|
Dysregulated immune responses to gut microbes are central to inflammatory bowel disease (IBD), and gut microbial activity can fuel chronic inflammation. Examining how IBD-directed therapies influence gut microbiomes may identify microbial community features integral to mitigating disease and maintaining health. However, IBD patients often receive multiple treatments during disease flares, confounding such analyses. Preclinical models of IBD with well-defined disease courses and opportunities for controlled treatment exposures provide a valuable solution. Here, we surveyed the gut microbiome of the T-bet(-/-) Rag2(-/-) mouse model of colitis during active disease and treatment-induced remission. Microbial features modified among these conditions included altered potential for carbohydrate and energy metabolism and bacterial pathogenesis, specifically cell motility and signal transduction pathways. We also observed an increased capacity for xenobiotics metabolism, including benzoate degradation, a pathway linking host adrenergic stress with enhanced bacterial virulence, and found decreased levels of fecal dopamine in active colitis. When transferred to gnotobiotic mice, gut microbiomes from mice with active disease versus treatment-induced remission elicited varying degrees of colitis. Thus, our study provides insight into specific microbial clades and pathways associated with health, active disease and treatment interventions in a mouse model of colitis.The ISME Journal advance online publication, 6 February 2014; doi:10.1038/ismej.2014.3.